Table 2 Overall survival (OS) and progression-free survival analysis (PFS)

Age

 ≤ 66 years

0.8249

0.7509

 > 66 years^R

(0.456–1.489)

(0.409–1.376)

Sex

 Male^R

1.715

1.740

 Female

(0.949–3.099)

(0.948–3.193)

ECOG

 0^R

 1

0.790 (0.402–1.556)

0.6893 (0.348–1.365)

 2–3

0.619 (0.247–1.554)

0.43 (0.1496–1.236)

Primary tumor location

 Head^R

1.16

1.295

 Body/tail

(0.596–2.275)

(0.6353–2.640)

Number of metastasis

 1

1.19

1.301

 ≥ 2^R

(0.652–2.169)

(0.703–2.405)

Metastatic location

 Hepatic^R

2.193

2.678

 Non-hepatic

(1.163–4.133)

(1.431–5.012)

RAS status in plasma

 MUT^R

2.605

2.850

 WT

(1.425–4.760)

(1.549–5.243)

MAF

 > 2.01%^R

1.591

1.813

 < 2.01%

(0.867–2.920)

(0.963–3.409)

CA19-9

 > 4515 U/mL^R

1.517

1.554

 < 4515 U/mL

(0.821–2.803)

(0.827–2.920)

cfDNA concentration

 > 31.8 ng/mL^R

1.858

1.853

 < 31.8 ng/mL

(0.999–3.451)

(0.973–3.526)

NPTX2 methylation

 > 6.06%^R

2.190

1.844

 < 6.06%

(1.186–4.044)

(0.989–3.437)